System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ahead of print

PubMed: 42828450 DOI: 10.1111/jdv.70769

Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa: A nationwide cohort study.

J Eur Acad Dermatol Venereol

Authors: Valdemar Wendelboe Nielsen, Nikolaj Holgersen, Nadja Højgaard Pedersen, Emma Brogaard, Yuki M F Andersen, Alexander Egeberg, Jacob P Thyssen, Simon Francis Thomsen

Affiliations

  • Department of Dermato-Venereology & Wound Healing Centre, Copenhagen University Hospital - Bispebjerg & Frederiksberg, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health of Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Abstract

BACKGROUND

Hidradenitis suppurativa (HS) is associated with obesity, metabolic dysfunction and increased healthcare utilization. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated anti-inflammatory effects and reduction in HS symptoms, but real-world patterns of GLP-1RA use in HS remain limited.

OBJECTIVES

To investigate GLP-1RA use and comorbidity burden among patients with HS compared to matched psoriasis patients and background controls, including changes in healthcare utilization and treatment patterns following GLP-1RA initiation.

METHODS

In this nationwide Danish register-based cohort study, adult patients with HS and age- and sex-matched patients with psoriasis and background controls were included from 1 January 2000 to 31 December 2022. Comorbidities were assessed at the date of HS diagnosis (index date) and at GLP-1RA initiation. Healthcare utilization, surgical procedures and medication use were examined during the 2 years before and after GLP-1RA initiation among patients with HS receiving continuous GLP-1RA treatment and matched HS non-users.

RESULTS

A total of 12,581 patients with HS, 9824 patients with psoriasis, and 12,581 controls were included. During follow-up, 8.2% of patients with HS initiated GLP-1RA treatment, compared with 5.7% of psoriasis patients and 3.2% of controls. Mean time to GLP-1RA initiation was shorter among patients with HS (8.88 years) than psoriasis patients (10.1 years; p < 0.001) and controls (10.2 years; p < 0.001). Cardiometabolic and psychiatric comorbidities increased from index date to treatment initiation across all groups. Following GLP-1RA initiation, lower rates of surgical procedures and systemic medication use were observed.

CONCLUSIONS

Patients with HS demonstrated earlier and more frequent use of GLP-1RA compared with psoriasis patients and controls, with decreased use of HS-specific treatments and surgical procedures following GLP-1RA initiation. Comparable declines were observed among matched non-initiators.

MeSH

Diabetes Mellitus, Glucagon-Like Peptide 1, Comorbidity, Glucagon-Like Peptide-1 Receptor, Exenatide, Surgical Procedures, Operative, Cardiovascular Diseases, Hidradenitis Suppurativa, Cohort Studies, Skin Diseases, Hidradenitis, Liraglutide, Obesity, Risk Factors, Glucagon, Therapeutics, Psoriasis, Glucagon-Like Peptides, Semaglutide